Kliesch S, Behre H M, Nieschlag E
Institute of Reproductive Medicine of the University, Münster, Germany.
Fertil Steril. 1995 Jun;63(6):1326-8. doi: 10.1016/s0015-0282(16)57619-5.
To determine the efficacy of recombinant FSH administration to induce spermatogenesis.
Case report, clinical study.
Tertiary center for reproductive medicine of the university.
A 44-year-old hypogonadal man with postpubertal pituitary insufficiency due to surgical removal of a prolactinoma.
Recombinant FSH (150 IU three times weekly) was administered together with hCG (1,500 IU twice weekly). Control examinations were performed every 6 weeks, including hormone determinations, safety parameters, testicular volume measurements, and semen analysis.
Semen parameters.
After 18 weeks of treatment, first sperm were seen in the ejaculate and reached normal sperm concentrations after 24 weeks of treatment. Serum hormone levels were in the normal range and testicular volume increased. No adverse side effects were observed.
Recombinant human FSH in combination with hCG can be used successfully for stimulation of testicular function in gonadotropin-deficient men.
确定重组促卵泡生成素(FSH)诱导精子发生的疗效。
病例报告、临床研究。
大学三级生殖医学中心。
一名44岁性腺功能减退男性,因手术切除催乳素瘤导致青春期后垂体功能不全。
重组FSH(每周三次,每次150国际单位)与hCG(每周两次,每次1500国际单位)联合使用。每6周进行一次对照检查,包括激素测定、安全参数、睾丸体积测量和精液分析。
精液参数。
治疗18周后,精液中首次出现精子,治疗24周后精子浓度达到正常水平。血清激素水平在正常范围内,睾丸体积增大。未观察到不良副作用。
重组人FSH联合hCG可成功用于刺激促性腺激素缺乏男性的睾丸功能。